Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...
The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...
The fate of the enhanced Affordable Care Act premium tax credits — initially bolstered during the pandemic — is still unclear ...
1d
Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.
Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...
Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.
A second magnificent ultra-high-yield dividend stock that's begging to be bought in November is pharmaceutical titan Pfizer ( ...
Pfizer saw U.S. Comirnaty sales drop to $870 million in the recently completed third quarter from $1.16 billion in the same ...
Shares of Pfizer Inc. gave up ground in early Tuesday trading, after the drug giant reported a decline in revenue, as ...
Vertex, Corteva, and many more will also report earnings. On the economic front, The Supreme Court will hear arguments on the legality of Trump’s tariffs, and ADP will release October employment data.
Real-time index price for Nasdaq Composite (NASX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...
The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...
U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback